Breast (Dec 2022)

Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer

  • Xu-Ran Zhao,
  • Yu Tang,
  • Hong-Fen Wu,
  • Qi-Shuai Guo,
  • Yu-Jing Zhang,
  • Mei Shi,
  • Jing Cheng,
  • Hong-Mei Wang,
  • Min Liu,
  • Chang-Ying Ma,
  • Ge Wen,
  • Xiao-hu Wang,
  • Hui Fang,
  • Hao Jing,
  • Yong-Wen Song,
  • Jing Jin,
  • Yue-Ping Liu,
  • Bo Chen,
  • Shu-Nan Qi,
  • Ning Li,
  • Yuan Tang,
  • Ning-Ning Lu,
  • Na Zhang,
  • Ye-Xiong Li,
  • Shu-Lian Wang

Journal volume & issue
Vol. 66
pp. 136 – 144

Abstract

Read online

Purpose: To assess the influence of age as a continuous variable on the prognosis of pT1-2N1 breast cancer and examine its decision-making value for postmastectomy radiotherapy (PMRT). Methods: We retrospectively evaluated 5438 patients with pT1-2N1 breast cancer after mastectomy in 11 hospitals. A multivariable Cox proportional hazards regression model with penalized splines was used to examine the relationship between age and oncologic outcomes. Results: The median follow-up was 67.0 months. After adjustments for confounding characteristics, nonsignificant downward trend in locoregional recurrence (LRR) risk was observed with increasing age (P-non-linear association = 0.640; P-linear association = 0.078). A significant non-linear association was found between age and disease-free survival (DFS) and overall survival (OS) (P-non-linear association 0.05, respectively). The DFS and OS exhibited U-shaped relationships, with the hazard ratios (HRs), reaching a nadir at 50 years old. A decreased risk of LRR with PMRT vs. no PMRT (HR = 0.304, 95% CI: 0.204–0.454) was maintained in all ages. The HR of PMRT vs. no PMRT for DFS and OS gradually increased with age. In patients ≤50 years old, PMRT was independently associated with favorable LRR, DFS, and OS, all P 50 years old, PMRT was independently associated with reduced LRR (P = 0.004), but had no effect on DFS or OS. Conclusions: Age was an independent prognostic factor for pT1-2N1 breast cancer; PMRT provided survival benefits for patients ≤50 years old, but not for patients >50 years old.

Keywords